首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme
【24h】

Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme

机译:灵活的乙状结肠镜筛查计划对非参与者的粪便进行免疫化学测试筛查

获取原文
获取原文并翻译 | 示例
           

摘要

Screening programmes based on single modality testing may prevent individuals with a preference for a different test from participating. We conducted a population-based trial to determine whether nonparticipants in flexible sigmoidoscopy (FS) screening were willing to attend faecal immunochemical test (FIT) screening. In total, 8,407 subjects were invited in a primary FS screening programme. Invitees did not know at the time of FS invitation that nonparticipants would be offered FIT screening. A total of 4,407 nonparticipants of FS screening were invited for FIT screening (cut-off 50 ng haemoglobin/ml). The participation rate to FS screening was 31% [95% confidence interval (CI): 30-32%]. Among the FS nonparticipants 25% (CI: 24-26%) did attended FIT screening. The participation rate of the two-stage recruitment for FS and FIT screening was 45% (CI: 44-46%). FIT screenees were older (p = 0.02), more often women (p < 0.001) and had a lower social economic status (p = 0.01) than FS screenees. The detection rate (DR) for advanced adenoma was 3.5% (CI: 2.5-4.8%), and for colorectal cancer (CRC) it was 0.3% (CI: 0.1-0.8%) among participants to FIT screening. The DR of the two-stage recruitment was 6.1% (n = 202) for an advanced adenoma and 0.5% (n = 16) for a CRC. In conclusion, offering FIT screening to nonparticipants in a FS screening programme increases the overall participation rate considerably, as a quarter of nonparticipants of FS screening was willing to attend FIT screening. The participation rate remains lower for primary FIT screening in the same population (62%). Women in the target population were more likely to refuse FS than FIT screening. Countries introducing FS screening should be aware of these preferences.
机译:基于单模态测试的筛查程序可能会阻止偏好其他测试的个人参与。我们进行了一项基于人群的试验,以确定非乙状结肠镜(FS)筛查的非参与者是否愿意参加粪便免疫化学测试(FIT)筛查。总共邀请了8,407名受试者参加初级FS筛查计划。受邀者在FS邀请时不知道未参加者将接受FIT筛查。总共邀请4,407名FS筛查的非参与者进行FIT筛查(临界值50 ng血红蛋白/ ml)。 FS筛查的参与率为31%[95%置信区间(CI):30-32%]。在FS非参与者中,有25%(CI:24-26%)参加了FIT筛查。 FS和FIT筛选的两阶段招聘参与率为45%(CI:44-46%)。与FS筛查者相比,FIT筛查者年龄较大(p = 0.02),女性较多(p <0.001),社会经济地位较低(p = 0.01)。在FIT筛查参与者中,晚期腺瘤的检出率(DR)为3.5%(CI:2.5-4.8%),对于结直肠癌(CRC)的检出率为0.3%(CI:0.1-0.8%)。对于晚期腺瘤,两阶段募集的DR为6.1%(n = 202),对于CRC为0.5%(n = 16)。总之,在FS筛查计划中为非参与者提供FIT筛查可显着提高总体参与率,因为四分之一的FS筛查的非参与者愿意参加FIT筛查。在相同人群中进行初次FIT筛查的参与率仍然较低(62%)。与FIT筛查相比,目标人群中的女性更可能拒绝FS。进行FS筛查的国家应了解这些偏好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号